PMID- 23372567
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130204
LR  - 20220330
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 3
DP  - 2012
TI  - Adoptive T-cell immunotherapy from third-party donors: characterization of donors 
      and set up of a T-cell donor registry.
PG  - 410
LID - 10.3389/fimmu.2012.00410 [doi]
LID - 410
AB  - Infection with and reactivation of human cytomegalovirus (CMV), Epstein-Barr 
      virus (EBV), and adenovirus (ADV) are frequent and severe complications in 
      immunocompromised recipients after hematopoietic stem cell transplantation (HSCT) 
      or solid organ transplantation (SOT). These serious adverse events are associated 
      with significant morbidity and mortality. Donor lymphocyte infusions (DLIs) are 
      often used to treat both viral infections and leukemia relapses after 
      transplantation but are associated with potentially life-threatening 
      graft-versus-host disease (GvHD). Adoptive immunotherapy with virus-specific 
      cytotoxic effector T cells (CTLs) derived from seropositive donors can rapidly 
      reconstitute antiviral immunity after HSCT and organ transplantation. Therefore, 
      it can effectively prevent the clinical manifestation of these viruses with no 
      significant acute toxicity or increased risk of GvHD. In conditions, where 
      patients receiving an allogeneic cord blood (CB) transplant or a transplant from 
      a virus-seronegative donor and since donor blood is generally not available for 
      solid organ recipients, allogeneic third party T-cell donors would offer an 
      alternative option. Recent studies showed that during granulocyte 
      colony-stimulating factor (G-CSF) mobilization, the functional activity of 
      antiviral memory T cells is impaired for a long period. This finding suggests 
      that even stem cell donors may not be the best source of T cells. Under these 
      circumstances, partially human leukocyte antigen (HLA)-matched virus-specific 
      CTLs from healthy seropositive individuals may be a promising option. Therefore, 
      frequency assessments of virus-specific memory T cells in HLA-typed healthy 
      donors as well as in HSCT/SOT donors using a high throughput T-cell assay were 
      performed over a period of 4 years at Hannover Medical School. This chapter will 
      address the relevance and potential of a third-party T-cell donor registry and 
      will discuss its clinical implication for adoptive T-cell immunotherapy.
FAU - Eiz-Vesper, Britta
AU  - Eiz-Vesper B
AD  - Institute for Transfusion Medicine, Hannover Medical School Hannover, Germany.
FAU - Maecker-Kolhoff, Britta
AU  - Maecker-Kolhoff B
FAU - Blasczyk, Rainer
AU  - Blasczyk R
LA  - eng
PT  - Journal Article
DEP - 20130128
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
PMC - PMC3556568
OTO - NOTNLM
OT  - Epstein-Barr virus
OT  - T-cell therapy
OT  - adenovirus
OT  - adoptive immunotherapy
OT  - antiviral T lymphocytes
OT  - cytomegalovirus
EDAT- 2013/02/02 06:00
MHDA- 2013/02/02 06:01
PMCR- 2012/01/01
CRDT- 2013/02/02 06:00
PHST- 2012/10/19 00:00 [received]
PHST- 2012/12/17 00:00 [accepted]
PHST- 2013/02/02 06:00 [entrez]
PHST- 2013/02/02 06:00 [pubmed]
PHST- 2013/02/02 06:01 [medline]
PHST- 2012/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2012.00410 [doi]
PST - epublish
SO  - Front Immunol. 2013 Jan 28;3:410. doi: 10.3389/fimmu.2012.00410. eCollection 
      2012.